Atlas Trials

Beijing Immunochina Medical Science & Technology Co., Ltd.

27 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Beijing Immunochina Medical Science & Technology Co., Ltd.

RecordFirmDate
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction (NCT07406984)Beijing Immunochina Medical Science & Technology Co., Ltd.2026-03-05
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus (NCT06886919)Beijing Immunochina Medical Science & Technology Co., Ltd.2025-03-31
Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus (NCT06852573)Beijing Immunochina Medical Science & Technology Co., Ltd.2025-02-20
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer (NCT06718738)Beijing Immunochina Medical Science & Technology Co., Ltd.2024-12-15
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients (NCT06690359)Beijing Immunochina Medical Science & Technology Co., Ltd.2024-12-13
WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients (NCT06691308)Beijing Immunochina Medical Science & Technology Co., Ltd.2024-11-12
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma (NCT06412458)Beijing Immunochina Medical Science & Technology Co., Ltd.2024-06-15
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia (NCT06209671)Beijing Immunochina Medical Science & Technology Co., Ltd.2024-01-15
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (NCT05480501)Beijing Immunochina Medical Science & Technology Co., Ltd.2022-07-11
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (NCT05309213)Beijing Immunochina Medical Science & Technology Co., Ltd.2022-04-01
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms (NCT05287165)Beijing Immunochina Medical Science & Technology Co., Ltd.2022-03-10
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma (NCT05275062)Beijing Immunochina Medical Science & Technology Co., Ltd.2022-02-15
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (NCT05117138)Beijing Immunochina Medical Science & Technology Co., Ltd.2022-01-01
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma (NCT05155215)Beijing Immunochina Medical Science & Technology Co., Ltd.2021-12-31
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors (NCT05123209)Beijing Immunochina Medical Science & Technology Co., Ltd.2021-08-24
Donor-derived CAR-T Cells in the Treatment of AML Patients (NCT04766840)Beijing Immunochina Medical Science & Technology Co., Ltd.2021-03-01
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma (NCT04537442)Beijing Immunochina Medical Science & Technology Co., Ltd.2020-09-03
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients (NCT04440436)Beijing Immunochina Medical Science & Technology Co., Ltd.2020-06-04
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors (NCT04951141)Beijing Immunochina Medical Science & Technology Co., Ltd.2019-01-01
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation (NCT04336501)Beijing Immunochina Medical Science & Technology Co., Ltd.2019-01-01
Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) (NCT03585517)Beijing Immunochina Medical Science & Technology Co., Ltd.2018-07-21
Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients (NCT03528421)Beijing Immunochina Medical Science & Technology Co., Ltd.2018-05-22
Safety and Efficacy Evaluation of Decitabine With R-GDP (NCT03535753)Beijing Immunochina Medical Science & Technology Co., Ltd.2017-09-01

Track Beijing Immunochina Medical Science & Technology Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.